NDNR Highlights Oxaloacetate as a Breakthrough for CFS & Long Covid
Share
We’re excited to share that oxaloacetate and our ongoing work in ME/CFS and Long COVID research were recently featured in NDNR (Naturopathic Doctor News & Review) in an article authored by Dr. Chris D. Meletis, N.D. The piece, “Oxaloacetate: A Missing Link in CFS, Long-Haul COVID, and Mitochondrial Performance,” highlights the growing scientific interest in oxaloacetate as a potential tool for addressing fatigue and mitochondrial dysfunction in post-viral conditions.
In the article, Dr. Meletis outlines the overlap between CFS and Long COVID and emphasizes mitochondrial impairment as a shared driver of symptoms such as fatigue, cognitive dysfunction, and reduced stress tolerance. He reviews recent clinical studies showing that stabilized oxaloacetate supplementation has led to measurable improvements in both mental and physical fatigue, including dose-dependent benefits in ME/CFS patients and up to a 46% reduction in fatigue among Long COVID participants.
Dr. Meletis also discusses key mechanisms associated with oxaloacetate, including mitochondrial biogenesis, improved NAD+/NADH balance, antioxidant activity, and reduction of neuroinflammation—factors that may play an important role in supporting recovery for patients with long-lasting post-viral symptoms.